Oncology

Latest News

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

By AJMC Contributor

July 23rd 2025

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.

Christine Pfaff, MBA, RPh | Image: LinkedIn

COA Welcomes Christine Pfaff, MBA, RPh, to Leadership Team

July 22nd 2025

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

By Hayden E. Klein
Robert Kratzke, MD

July 22nd 2025

Cancer diagnosis financial strain | Image Credit: Maggie-sort.chatgpt.com

Cancer Diagnoses Bring Major Financial Burden for Privately Insured Adults

By Maggie L. Shaw

July 21st 2025

COVID-19 vaccine for patients with cancer. | Image Credit: Framestock - stock.adobe.com

COVID-19 Boosters Crucial for Patients With Cancer Despite Low Uptake

By Cameron Santoro

July 17th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

July 23rd 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 23rd 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Dr Joseph Alvarnas Addresses Rising Medical Costs

September 13th 2015

Dr Joseph Alvarnas Addresses Rising Medical Costs

Healthcare practitioners are well aware that the rising cost of medical advances may affect their ability to deliver great care to all their patients, but there are ways they can address the issue, said Joseph Alvarnas, MD, the editor-in-chief of Evidence-Based Oncology.

September 11th 2015

Immune Treatments in Cancer Need Additional Vigilance and Earlier Recognition

Surabhi Dangi-Garimella, PhD

An abstract presented at the 16th World Conference on Lung Cancer presented results from a study that monitored irAEs resulting from treatment with immune checkpoint inhibitors.

September 10th 2015

Study Identifies Actionable Mutations in Young Lung Cancer Patients

Surabhi Dangi-Garimella, PhD

Presented at the ongoing World Conference on Lung Cancer, the trial has identified 7 actionable genomic alterations in lung cancer patients under 40 years of age.

Kim Thiboldeaux Explains Patient Misconceptions of Cancer Clinical Trials

September 10th 2015

Kim Thiboldeaux Explains Patient Misconceptions of Cancer Clinical Trials

Kim Thiboldeaux, chief executive officer of the Cancer Support Community, discusses the importance of providing strong community support, the misconceptions of clinical trials, and creating a tailored care plan.

September 10th 2015

ASCO Submits Comments on the Proposed Medicare Physician Fee Schedule Rules

Surabhi Dangi-Garimella, PhD

At the end of CMS' comment period, the American Society of Clinical Oncology submitted its comments and recommendations for the proposed changes.

September 9th 2015

CalPERS Successfully Implemented Reference Payment to Save on Colonoscopy Costs

Surabhi Dangi-Garimella, PhD

The California Public Employees' Retirement System saved $7 million on screening colonoscopies during a 2-year period following implementation of reference pricing.

September 9th 2015

FDA Grants Priority Review for Alectinib in Advanced NSCLC Resistant to Crizotinib

Surabhi Dangi-Garimella, PhD

The drug, approved in Japan last year, had been granted Breakthrough Therapy designation by the FDA.

September 8th 2015

Preliminary Results Promising for Opdivo-Yervoy as First-Line in Advanced NSCLC

Surabhi Dangi-Garimella, PhD

With a new dosing schedule, low toxicity and a PD-L1 expression-driven response was observed.

September 8th 2015

CMS Changes to Physician Fee Schedule Face Resistance From Radiation Oncologists

Surabhi Dangi-Garimella, PhD

With the comment period ending today, the proposed CMS cuts to radiation oncology reimbursement rates might have a substantial impact on community treatment centers.

September 7th 2015

CVS: Taking Tobacco From Stores Prompted Quit Attempts; Sales of Cigarettes Dropped

Mary K. Caffrey

Data in study show removal of tobacco from stores led to surge in purchase of nicotine patches.

September 7th 2015

Keytruda Gains NICE Approval While Kadcyla Fails

Surabhi Dangi-Garimella, PhD

Cancer drug cost troubles in the UK prompt NHS to slash its list of approved-for-use oncology products.

Dr Amy Davidoff Examines Factors Influencing Patient Treatment Decisions in Cancer Care

September 7th 2015

Dr Amy Davidoff Examines Factors Influencing Patient Treatment Decisions in Cancer Care

For individuals who have not made the sort of risk-averse decisions in their lives that lead to better jobs and wealth accumulation, making treatment decisions after a cancer diagnosis can be very difficult, said Amy Davidoff, PhD, MS, senior research scientist in public health at the Yale School of Public Health

September 7th 2015

Watch and Wait Feasible in Nearly 70% of Men With Prostate Cancer, Study Suggests

Surabhi Dangi-Garimella, PhD

Urologists analyzing data from prostate cancer patients suggest wait and watch in well-informed low-risk prostate cancer patients.

Dr Robert Dubois Outlines the Creation, Utilization of Clinical Pathways

September 6th 2015

Dr Robert Dubois Outlines the Creation, Utilization of Clinical Pathways

A survey of groups using and developing clinical pathways revealed 7 distinct themes that highlight how these pathways are created and used, and the challenges and barriers to creating new pathways, explained Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.

September 4th 2015

Integrating Genomics into Pediatric Cancer Care

Surabhi Dangi-Garimella, PhD

Study provides proof that a child's genetic makeup can provide actionable information to alter cancer treatment regimens.

September 3rd 2015

Long-Anticipated Biosimilar From Novartis Launched, but at What Price?

Surabhi Dangi-Garimella, PhD

Novartis has announced that Zarxio will be available at 15% of the cost of its reference product Neupogen.

September 3rd 2015

Prophylactic Breast Surgery on the Rise in Men With Breast Cancer

Surabhi Dangi-Garimella, PhD

Men are opting for preventive breast surgery when diagnosed with unilateral invasive disease, a study published in JAMA Surgery has found.

September 2nd 2015

Telehealth Intervention Can Overcome Barriers to Colorectal Screening

Surabhi Dangi-Garimella, PhD

Personalized telephone counseling and tailored educational materials can improve colonoscopy rates among at-risk family members of patients with colorectal cancer.

September 2nd 2015

Rolapitant Gains FDA Approval for CINV

Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.

September 1st 2015

ASCO Publishes Policy Update on Genomic Testing for Cancer Susceptibility

Surabhi Dangi-Garimella, PhD

The Cancer Prevention and Ethics Committees of the American Society of Clinical Oncology have made several recommendations that address genetic and genomic testing policies for cancer risk assessment.

Mary Lou Smith on Ensuring Patients' Voices Are Heard

September 1st 2015

Mary Lou Smith on Ensuring Patients' Voices Are Heard

Sometimes patients are so concerned with being good patients that they simply agree to what the clinician has said without fully understanding, and it's important to ask questions and ensure their voices are heard, said Mary Lou Smith, MBA, co-founder of the Research Advocacy Network.

September 1st 2015

Elotuzumab Accepted for Priority Review by FDA for Previously-Treated Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The submission by BMS includes results from the ELOQUENT-2 trial that were recently published in the New England Journal of Medicine.

August 31st 2015

Gene Signature Could Predict Development of Pancreatic Cancer, Allow Personalized Treatment

Surabhi Dangi-Garimella, PhD

A novel microRNA gene signature could guide earlier intervention in pancreatic cancer.

August 31st 2015

ASCO Updates Guidelines for Advanced Lung Cancer

Surabhi Dangi-Garimella, PhD

An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.

August 31st 2015

New 340B Draft Guidance May Increase Bureaucracy

Surabhi Dangi-Garimella, PhD

The new guidance released by HRSA proposes to improve oversight over the drug pricing program.

August 30th 2015

Pharmacy Cost Trends Expected to Continue in the Double Digits

Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health.

August 28th 2015

Protein Biomarker Can Predict Response to FOLFIRINOX in Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.

Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care

August 28th 2015

Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

August 27th 2015

Childhood Cancer Increases Risk of Recurrent Stroke

Surabhi Dangi-Garimella, PhD

Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.

August 27th 2015

A New Decision Support Tool for Surgical Oncology Launched

A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.

...

123 124 125 126 127 128 129 130 131

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions